



CENTRAL MEDICAL SERVICES SOCIETY

(An Autonomous Body, Ministry of Health & Family Welfare, Govt. of India)

2nd Floor, Vishwa Yuvak Kendra, Teen Murti Marg,

Chanakypuri, New Delhi-110021.

Website: www.cmss.gov.in, Tel. 011-21410905/6

Dated: 03-12-2025

Minutes of Pre-Bid Meeting and Amendment No. 01

RC Tender for:- Procurement and Supply of Tablets Sofosbuvir 400 mg and Daclatasvir 60 mg for the National Viral Hepatitis Control Program (NVHCP)

RC Tender No: - CMSS/PROC/2025-26/NVHCP/033, Dt.18-11-2025
(CPP ID: 2025_CMSS_886065_1),

Pre-bid Meeting held on: - 26-11-2025 at 11:00 AM

Points raised by the representatives of prospective bidders were discussed. After due consideration of the queries, the Pre-bid clarification is enclosed herewith. Further, the following Amendments are hereby made to above referred tender document: -

1) SECTION V: SCHEDULE OF REQUIREMENTS; B. DELIVERY SCHEDULE; PAGE 63;

FOR: -

B. Delivery Schedule: -

Sch No.	Name of Item	Quantity (in Tablets)- to be delivered within 60 days from the date of issuance of Purchase Order	Quantity (in Tablets)- to be delivered within 120 days from the date of Issuance of Purchase Order
I.	Sofosbuvir 400 mg (Regular Tender Schedule)	26,24,104	23,23,852
II.	Daclatasvir 60 mg (Regular Tender Schedule)	26,24,104	23,23,852
III.	Sofosbuvir 400 mg (Developmental Tender Schedule)	6,56,040	6,55,928
IV.	Daclatasvir 60 mg (Developmental Tender Schedule)	6,56,040	6,55,928

AMENDED TO BE READ AS:

B. Delivery Schedule: -

Sch No.	Name of Item	Quantity (in Tablets)- to be delivered within 60 days from the date of issuance of Purchase Order	Quantity (in Tablets)- to be delivered within <u>61-120 days</u> from the date of Issuance of Purchase Order
I.	Sofosbuvir 400 mg (Regular Tender Schedule)	26,24,104	26,23,852
II.	Daclatasvir 60 mg (Regular Tender Schedule)	26,24,104	26,23,852
III.	Sofosbuvir 400 mg (Developmental Tender Schedule)	6,56,040	6,55,928
IV.	Daclatasvir 60 mg (Developmental Tender Schedule)	6,56,040	6,55,928

**2) SECTION VI: TECHNICAL SPECIFICATIONS AND QUALITY ASSURANCE;
PAGE 64; 1. Sofosbuvir**

FOR: -

Point No. 03:- Should be licensed as per (IH/IP) under the provision of drugs and cosmetic act 1940 and rules made there under.

AMENDED TO BE READ AS:

Point No. 03:- Should be licensed as per (IP) under the provision of drugs and cosmetic act 1940 and rules made there under.

3) Further, The IMPORTANT TIMELINES for submission of original documents for the above referred tender have been amended as follows:

Particulars	Existing	Amended As
<u>Last date and time for bid submission</u>	<u>11/12/2025 till 03:00 PM</u>	-No Change-
Last date and time for submission of original documents	11/12/2025 till 03:00 PM	12/12/2025 till 03:00 PM
Date and time for tender opening (technical bid)	12/12/2025 at 04:00 PM	-No Change-

Note: -Apart from above, all other terms and conditions of bid document shall remain unchanged.

Sd/-
Joint Director (Procurement)

Tender No.:- CMSS/PROC/2025-26/NVHCP/033, Dt.18-11-2025
Tender for:- Procurement and Supply of Tablets Sofosbuvir 400 mg and Daclatasvir 60 mg for the National Viral Hepatitis Control Program (NVHCP)
Pre-bid meeting held on:- 26-11-2025 @ 11:00 AM

Sr. No.	Pg. No. and Clause as per Tender document	Tender Brief Descriptions	Bidder(s) Name (M/s)	Bidder's Query / Suggestion / Proposed modification	Clarification(s)/ Amendment(s)																				
1	Section V – Schedule of Requirement; B. Delivery Schedule (Pg # 63 of 184)	<table><thead><tr><th>Sch No.</th><th>Name of Item</th><th>Quantity (in Tablets)- to be delivered within 60 days from the date of issuance of Purchase Order</th><th>Quantity (in Tablets)- to be delivered within 120 days from the date of Issuance of Purchase Order</th></tr></thead><tbody><tr><td>I.</td><td>Sofosbuvir 400 mg (Regular Tender Schedule)</td><td>26,24,104</td><td>23,23,852</td></tr><tr><td>II.</td><td>Daclatasvir 60 mg (Regular Tender Schedule)</td><td>26,24,104</td><td>23,23,852</td></tr><tr><td>III.</td><td>Sofosbuvir 400 mg (Developmental Tender Schedule)</td><td>6,56,040</td><td>6,55,928</td></tr><tr><td>IV.</td><td>Daclatasvir 60 mg (Developmental Tender Schedule)</td><td>6,56,040</td><td>6,55,928</td></tr></tbody></table>	Sch No.	Name of Item	Quantity (in Tablets)- to be delivered within 60 days from the date of issuance of Purchase Order	Quantity (in Tablets)- to be delivered within 120 days from the date of Issuance of Purchase Order	I.	Sofosbuvir 400 mg (Regular Tender Schedule)	26,24,104	23,23,852	II.	Daclatasvir 60 mg (Regular Tender Schedule)	26,24,104	23,23,852	III.	Sofosbuvir 400 mg (Developmental Tender Schedule)	6,56,040	6,55,928	IV.	Daclatasvir 60 mg (Developmental Tender Schedule)	6,56,040	6,55,928	Mylan Laboratories Ltd.	B. Delivery Schedule: The delivery schedule is given for approximately 23% of the tender quantity. Kindly provide a delivery schedule for at least 50% of the tender quantity, as the API lead time is a minimum of six months. It helps RC holders make better plans for your supplies.	Please refer to Amendment No.01 It is clarified that the delivery schedule stipulated corresponds to approximately 25% of the quantity to be supplied during the first six months of the Rate Contract period. The requirement indicated for the two-year duration is tentative. Placement of further Purchase Orders will be based on the Programme Division's requirements, within the validity of the Rate Contract period.
Sch No.	Name of Item	Quantity (in Tablets)- to be delivered within 60 days from the date of issuance of Purchase Order	Quantity (in Tablets)- to be delivered within 120 days from the date of Issuance of Purchase Order																						
I.	Sofosbuvir 400 mg (Regular Tender Schedule)	26,24,104	23,23,852																						
II.	Daclatasvir 60 mg (Regular Tender Schedule)	26,24,104	23,23,852																						
III.	Sofosbuvir 400 mg (Developmental Tender Schedule)	6,56,040	6,55,928																						
IV.	Daclatasvir 60 mg (Developmental Tender Schedule)	6,56,040	6,55,928																						
2	Section VI – Technical Specification and Quality Assurance: (Pg # 64 of 184)	Sofosbuvir 400 mg Tablet:- Point No. 03:- Should be licensed as per (IH/IP) under the provision of drugs and cosmetic act 1940 and rules made there under.	Hetero Labs Ltd.	Please note that Tab. Sofosbuvir 400mg is covered under Indian Pharmacopeia and is manufactured in accordance with IP standards for the Indian Market. It is therefore requested that the said clause may please be amended as below: Technical Specification, Point 3: Should be licensed (as per IP) under the provisions of Drugs and Cosmetics Act 1940 and Rules, made there under	Please refer to Amendment No.01																				

Note:- Above Clarifications/amendment will be part of the tender document.

Sd/-
Joint Director (Procurement)